Show simple item record

dc.contributor.authorMiljević, Cedo
dc.contributor.authorNikolić-Kokić, Aleksandra
dc.contributor.authorSaicić, Zorica S
dc.contributor.authorMilosavljević, Maja
dc.contributor.authorBlagojević, Dusko
dc.contributor.authorTosevski, Dusica Lecić
dc.contributor.authorJones, David R
dc.contributor.authorSpasić, Mihajlo B
dc.date.accessioned2010-09-18T08:43:47Z
dc.date.available2010-09-18T08:43:47Z
dc.date.issued2010-06-30
dc.identifier.citationCorrelation analysis confirms differences in antioxidant defence in the blood of types I and II schizophrenic male patients treated with anti-psychotic medication. 2010, 178 (1):68-72 Psychiatry Resen
dc.identifier.issn0165-1781
dc.identifier.pmid20452039
dc.identifier.doi10.1016/j.psychres.2008.10.038
dc.identifier.urihttp://hdl.handle.net/10541/111373
dc.description.abstractThe activities of antioxidant defence enzymes were determined in erythrocytes isolated from types I and II schizophrenic male patients and from healthy controls. Significant differences in superoxide dismutase (SOD) activity (type I: 3284+/-577; type II: 2959+/-697 compared with controls: 3778+/-577; analysis of variance (ANOVA) P<0.001), catalase (CAT) activity (type I: 17.8+/-1.8 compared to type II: 19.2+/-1.5 and both compared with controls: 19.2+/-1.5; ANOVA P<0.05), glutathione peroxidase (GSH-Px) activity (controls: 17.8+/-2.3; type I: 13.9+/-2.9 and type II: 11.6+/-1.9; ANOVA P<0.001) as well as in glutathione reductase (GR) activity (controls: 5,0+/-0.8; type I: 4.3+/-0.9 and type II: 4.5+/-0.8; ANOVA P<0.01) were apparent. Correlation analysis of antioxidant defence enzymes showed significant negative correlation between GSH-Px and CAT activities (P<0.01) in type I patients. In type II patients, GSH-Px activity was significantly positively correlated with GR (P<0.01). Canonical discriminant analysis separated type I and type II patients from controls (and among each other) with a high degree of certainty according to the overall group composition of antioxidant defence enzymes. Our results indicate differences in the composition of antioxidant defence between controls and anti-psychotic treated type I and type II patients with a possible negative feedback influence on the pathological process, which could provide a rationale for applying antioxidants during schizophrenic therapy.
dc.language.isoenen
dc.subjectSchizophreniaen
dc.subjectErythrocytesen
dc.subjectOxidative Stressen
dc.subjectSuperoxide Dismutaseen
dc.subjectCatalaseen
dc.titleCorrelation analysis confirms differences in antioxidant defence in the blood of types I and II schizophrenic male patients treated with anti-psychotic medication.en
dc.typeArticleen
dc.identifier.eissn1872-7123
dc.contributor.departmentInstitute of Mental health, Palmotićeva 37, Belgrade, Serbia.en
dc.identifier.journalPsychiatry Researchen
html.description.abstractThe activities of antioxidant defence enzymes were determined in erythrocytes isolated from types I and II schizophrenic male patients and from healthy controls. Significant differences in superoxide dismutase (SOD) activity (type I: 3284+/-577; type II: 2959+/-697 compared with controls: 3778+/-577; analysis of variance (ANOVA) P<0.001), catalase (CAT) activity (type I: 17.8+/-1.8 compared to type II: 19.2+/-1.5 and both compared with controls: 19.2+/-1.5; ANOVA P<0.05), glutathione peroxidase (GSH-Px) activity (controls: 17.8+/-2.3; type I: 13.9+/-2.9 and type II: 11.6+/-1.9; ANOVA P<0.001) as well as in glutathione reductase (GR) activity (controls: 5,0+/-0.8; type I: 4.3+/-0.9 and type II: 4.5+/-0.8; ANOVA P<0.01) were apparent. Correlation analysis of antioxidant defence enzymes showed significant negative correlation between GSH-Px and CAT activities (P<0.01) in type I patients. In type II patients, GSH-Px activity was significantly positively correlated with GR (P<0.01). Canonical discriminant analysis separated type I and type II patients from controls (and among each other) with a high degree of certainty according to the overall group composition of antioxidant defence enzymes. Our results indicate differences in the composition of antioxidant defence between controls and anti-psychotic treated type I and type II patients with a possible negative feedback influence on the pathological process, which could provide a rationale for applying antioxidants during schizophrenic therapy.


Files in this item

This item appears in the following Collection(s)

Show simple item record